secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2025-02-24T23:59:59+00:00
Accession:  0001493152-25-008080
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo faces Nasdaq delisting risk after change of control; enters lock-up with 22NW
--------------------------------------------------------------------------------

- Nasdaq determined that Dec 2024 private placement caused a change of control, violating Listing Rule 5635(b); company received notice Feb 20, 2025.
- Company entered lock-up agreement with 22NW (Aron English) on Feb 24, 2025, restricting voting/sale of 10.1M shares until stockholder approval.
- Nasdaq granted extension until April 10, 2025 to obtain stockholder approval; annual meeting scheduled April 4, 2025.
- Joseph Lawler entities have agreed to vote in favor of removing lock-up restrictions, which would ratify the change of control.
- Failure to obtain stockholder approval by April 10, 2025 may result in delisting from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225008080/0001493152-25-008080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315225008080/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer